Last reviewed · How we verify
NCT05112627
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy
trial testing Biospecimen Collection in Metastatic Renal Cell Carcinoma in 15 participants. Completed in 15 May 2024.
15 May 2024
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 24 January 2022 |
| Primary completion | 15 May 2024 |
| Estimated completion | 15 May 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Biospecimen Collection — full drug profile →
Conditions studied
- Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →
- Stage IV Renal Cell Cancer AJCC v8 — all drugs for Stage IV Renal Cell Cancer AJCC v8 →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Metastatic Renal Cell Carcinoma or Stage IV Renal Cell Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application.
Li M, Li L, Zheng J, Li Z, et al · · 2023 · cited 57× · PMID 36810071 · DOI 10.1186/s12943-023-01745-7 -
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.
Anderson AC, Ho J, Hall ET, Hannan R, et al · · 2024 · cited 4× · PMID 39258792 · DOI 10.1080/14796694.2024.2389769
Verify or expand the search:
- PubMed search for NCT05112627
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen Collection
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Metastatic Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
- NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
- NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
- NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05112627 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05112627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing